Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 18/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537258 | 0.80 | MAP4K4 (1.00) | MAP4K4 | |
| Hydrochloric Acid SCHEMBL18129021 | 0.79 | MAP4K4 (0.98) | MAP4K4 | |
| SCHEMBL15537863 | 0.78 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL15587833 | 0.78 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL15587791 | 0.77 | MAP4K4 (0.67) | MAP4K4 | |
| SCHEMBL15537350 | 0.76 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL15537342 | 0.75 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL15587826 | 0.75 | MAP4K4 (1.00) | MAP4K4 | |
| SCHEMBL1035448 | 0.75 | MAP4K4 (0.74) | MAP4K4 | |
| SCHEMBL12441623 | 0.75 | MAP4K4 (0.60) | MAP4K4LTA4HBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855459-B1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | claimed |
| EP-2855459-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | claimed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | claimed |
| EP-2855459-B1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9855269-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592235-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382241-B2 | Aminoquinazoline and pyridopyrimidine derivatives | GENENTECH, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| EP-2855459-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160296525-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | DPYD, FANCD2, RECQL | MAP4K4 700/4885LTA4H 3293/4885BACE1 4230/4885 |
| US-20170173026-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | FLT4, FLT1, KDR | MAP4K4 662/4885LTA4H 2666/4885BACE1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.